• LAST PRICE
    2.2400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.1600/ 1
  • Ask / Lots
    2.3000/ 83
  • Open / Previous Close
    0.0000 / 2.2400
  • Day Range
    ---
  • 52 Week Range
    Low 1.0900
    High 4.3200
  • Volume
    5
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeINKT
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesINKT
Mink Therapeutics Inc
75.7M
-2.9x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
75.6M
-8.7x
---
United StatesMBIO
Mustang Bio Inc
75.5M
-0.9x
---
United StatesVIRX
Viracta Therapeutics Inc
74.9M
-1.5x
---
United StatesSPRB
Spruce Biosciences Inc
74.7M
-1.7x
---
United StatesONCY
Oncolytics Biotech Inc
103.5M
-5.5x
---
As of 2023-02-08

Company Information

MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The Company offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.

Contact Information

Headquarters
149 Fifth Avenue, Suite 500NEW YORK, NY, United States 10010
Phone
212-994-8250
Fax
302-655-5049

Executives

Chairman of the Board
Garo Armen
President, Chief Executive Officer, Director
Jennifer Buell
Chief Scientific Officer
Marc Van Dijk
Treasurer
Christine Klaskin
Independent Director
John Baldoni

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$75.7M
Revenue (TTM)
$0.00
Shares Outstanding
33.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.78
Book Value
$0.71
P/E Ratio
-2.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.